Jim Cramer
Here is Eli Lilly's competitive edge in GLP-1 obesity drugs and Abbott's secondary play
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Inflation relief: The stock market was […]
Read More
One down one to go — what we learned from TJX's great quarter and hope to hear from Salesforce
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. 1. U.S. stocks were trending lower as investors awaited important inflation data and mulled over more quarterly earnings. January’s PCE price index – the Federal Reserve’s preferred measure of inflation […]
Read More
Jim Cramer says buy this data center equipment firm despite its weak guidance
Vertiv Holdings : The data center equipment maker, whose shares have roughly quadrupled over the past year, issued guidance that didn’t live up to Wall Street’s lofty expectations. However, the stock is now trading well off its lows of the morning. “Data center still strong. Buy,” Jim Cramer said. Teladoc Health : Shares tumbled 24% […]
Read More
In this fast-paced bull market, we're increasing our Club price targets on 4 stocks
It’s been hard to keep up. That’s the story of the big stock winners this year. They just keep winning and winning and winning. For analysts on Wall Street and here at the Club, it seems like some of these names are smashing through our six-to-nine-month price targets every few weeks. To that end, we’re […]
Read More
What Eli Lilly investors can learn from the slow launch of a competitor's drug
Club holding Eli Lilly is expecting to get approval for its Alzheimer’s treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. On its fourth-quarter earnings call Tuesday, rival drugmaker Biogen shared data that showed its therapy for the memory-robbing disease, Leqembi, is off to a slower-than-expected start. In […]
Read More
Jim Cramer praises GE following U.S. regulatory approval to develop nuclear fuel
CNBC’s Jim Cramer called out General Electric as a winner in the industrial sector for the strides it’s making in nuclear power. GE’s Verona Nuclear Fuel business said Wednesday it received approval from the U.S. Nuclear Regulatory Commission to manufacture, ship, and analyze the performance of higher enrichment fuel. These “regulatory milestones” will help the […]
Read More
Here's why we would be considering buying more Eli Lilly shares if they were down Tuesday
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks tumbled Tuesday on hotter-than-expected retail inflation data. The surprise uptick in the January consumer price index sent bond yields higher and the Dow , the S & […]
Read More
Wall Street changes its tune on this healthcare stock. Why we were always bullish
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1. U.S. stocks were modestly higher Monday as the market awaits key economic data. Traders will be mulling over the consumer price index Tuesday, retail sales Thursday, and the producer […]
Read More
Portfolio health care name turns its luck around thanks to management's AI push
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. U.S. stocks were mostly higher on Friday. The S & P 500 was on track for a fifth positive week in a row. The broad market index topped 5,000 […]
Read More
Expedia shares plunge on weak air journey bookings and information the CEO is stepping down
Expedia shares sank 19% on Friday just after the firm noticed softness in air travel bookings and its CEO resigned. CNBC’s Jim Cramer said the magnitude of the stock drop may be an overreaction. Although providing an earnings-per-share defeat and in-line profits in the fourth quarter, bookings fell brief, “mostly driven by a reduction in […]
Read More